[Comment] Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use

The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 (SGLT2) inhibitors, a class of drugs with benefits extending well beyond glycaemic control. In The Lancet Diabetes & Endocrinology, William G Herrington and colleagues1 present an individual participant-level meta-analysis encompassing 23 340 participants from four landmark placebo-controlled empagliflozin trials, representing a step forward in our understanding of the renal effects of empagliflozin across a spectrum of populations.